{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:55:31Z","timestamp":1791809731269,"version":"4.3.4"},"reference-count":30,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T00:00:00Z","timestamp":1762992000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"NHS England"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Clin Biochem"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Point of care (POC) tests may improve accessibility and reduce costs of blood tests including in prostate cancer. The Man Van project was a pilot designed to address health inequalities that affect prostate cancer with novel community-based targeting of high-risk groups on a mobile clinical unit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The i-CHROMA-II\u2122 POC machine is a quantitative assay for the measurement of total prostate specific antigen (PSA) from capillary blood using fluorescence immunoassay technology. Laboratory based Serum PSA testing was compared with capillary blood POC testing using the i-CHROMA-II\u2122 to determine its accuracy and impact on clinical decision making on the Man Van.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>28 men participated. The median age was 53\u00a0years (range 45\u201374). One POC test result was invalid. Nine POCT samples gave a result of &lt;0.5\u00a0\u03bcg\/L and were not included in the analysis. Of the remaining results (N = 18) the median PSA was 1.97\u00a0\u03bcg\/L (range 0.54-31.22\u00a0\u03bcg\/L). Using Lin\u2019s Concordance Correlation Coefficient of Absolute Agreement gave a value of 0.392 (N = 17). A Bland-Altman plot showed a mean difference of 0.377\u00a0\u03bcg\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We report the first testing of PSA using the i-Chroma-II\u2122 machine, and the first real-world mobile testing using any POC PSA test. Our study did not show correlation between the laboratory and i-Chroma-II\u2122, although it did replicate the positive bias seen in previous studies. Further testing and refinement of POC tests may help to achieve the goal to developing reliable POC PSA tests.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/00045632251398445","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T10:16:51Z","timestamp":1762337811000},"page":"301-307","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of a point of care prostate-specific antigen blood test on a mobile outreach service"],"prefix":"10.1177","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-5031","authenticated-orcid":false,"given":"Masood","family":"Moghul","sequence":"first","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust"},{"name":"The Institute of Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Berry","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freeda","family":"Millet","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Tran","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Mutch","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Westaway","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fionnuala","family":"Croft","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn","family":"Shea","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Netty","family":"Kinsella","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kierkegaard","sequence":"additional","affiliation":[{"name":"Imperial College London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Declan","family":"Cahill","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas David","family":"James","sequence":"additional","affiliation":[{"name":"The Royal Marsden NHS Foundation Trust"},{"name":"The Institute of Cancer Research"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,11,13]]},"reference":[{"key":"e_1_3_4_2_2","unstructured":"Cancer Research UK. Prostate Cancer Statistics. https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer (accessed Jan 10 25)."},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00651-2"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/POC.0000000000000214"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/42.5.711"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.316.7137.1052"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/MAJ.0b013e3181637417"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/irv.12359"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2016.08.003"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1586\/14737159.2015.976202"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/2050640618761700"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1021\/acssensors.3c01402"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810696"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2019.02.009"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214122"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61611-0"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2209454"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801993"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-021-00438-w"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.euros.2023.05.011"},{"key":"e_1_3_4_21_2","unstructured":"Europa Uoma - News Page. 2024. https:\/\/www.europa-uomo.org\/news\/national-prostate-screening-programme-underway-in-czech-republic\/#:\u223c:text= The new Czech national screening to a urologist if neccessary. (accessed Aug 29 2024)."},{"key":"e_1_3_4_22_2","unstructured":"National Health Service of Latvia. Preventive cancer screening. 2023. https:\/\/www.vmnvd.gov.lv\/en\/preventive-cancer-screening?utm_source=https%3A%2F%2Fwww.google.com%2F (accessed Aug 29 2024)."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/POC.0000000000000131"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/clinpract13040078"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35169"},{"key":"e_1_3_4_26_2","volume-title":"GIRFT urology: towards better diagnosis & management of suspected prostate cancer","author":"Moore C","year":"2024","unstructured":"Moore C, McGrath J, O\u2019Flynn K. GIRFT urology: towards better diagnosis & management of suspected prostate cancer, 2024. https:\/\/gettingitrightfirsttime.co.uk\/wp-content\/uploads\/2024\/04\/GIRFT-Urology-Towards-Better-Diagnosis-Management-of-Suspected-Prostate-Cancer-FINAL-V1-April-2024-1.pdf"},{"key":"e_1_3_4_27_2","volume-title":"INS-PS-EN","author":"Boditech. ichroma TM PSA","year":"2016","unstructured":"Boditech. ichroma TM PSA. INS-PS-EN. 19th edn. Boditech, 2016. https:\/\/panta-co.com\/editor\/product\/PSA1.pdf","edition":"19"},{"key":"e_1_3_4_28_2","unstructured":"Bolodeoku J Coker O Bains S et al. The performance of the Point of Care Test (POCT) I-CHROMATM PSA method using internal and external quality assessment schemes: United Kingdom External Quality Assessment Service (UKNEQAS) And Randox International Quality Assessment Service (RIQAS). Curr Trends Med Diagn Methods 2018; 2: 1. CTMDM-104."},{"key":"e_1_3_4_29_2","first-page":"1","article-title":"An evaluation of the novel i-CHROMATM point-of-care testing (POCT) method for the analysis of prostate-specific antigen (PSA) in serum","volume":"9","author":"Beltran L","year":"2018","unstructured":"Beltran L, Leach E, de Fonseka S, et al. An evaluation of the novel i-CHROMATM point-of-care testing (POCT) method for the analysis of prostate-specific antigen (PSA) in serum. Biomed J Sci Tech Res 2018; 9: 1\u20135.","journal-title":"Biomed J Sci Tech Res"},{"key":"e_1_3_4_30_2","unstructured":"Boditech. i-Chroma II key features. 2021. https:\/\/www.boditech.co.kr\/en\/support\/id\/144 (accessed Aug 23 2024)."},{"key":"e_1_3_4_31_2","unstructured":"NICE. NICE GuidelinesProstate cancer: How should I assess a person with suspected prostate cancer? 2025. https:\/\/cks.nice.org.uk\/topics\/prostate-cancer\/diagnosis\/assessment\/"}],"container-title":["Annals of Clinical Biochemistry: International Journal of Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00045632251398445","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00045632251398445","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00045632251398445","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T23:22:32Z","timestamp":1783207352000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00045632251398445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,13]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/00045632251398445"],"URL":"https:\/\/doi.org\/10.1177\/00045632251398445","relation":{},"ISSN":["0004-5632","1758-1001"],"issn-type":[{"value":"0004-5632","type":"print"},{"value":"1758-1001","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,13]]}}}